The TTxD development pipeline entails three preclinical programs. Our RIDE-001 program focuses on nanobiologic therapeutics for the treatment of solid tumors. RIDE-002 program focuses on nanobiologic therapeutics to treat allograft rejection in transplantation. For the treatment of acute and chronic inflammatory diseases RIDE-003 was developed.

 

Multiple undisclosed discovery programs complete the current TTxD pipeline.

In parallel TTxD continues the development of it’s proprietary nanobiologic platform.